Syndax Pharmaceuticals prices IPO at $12 per share
March 04, 2016
Clinical stage biopharma Syndax Pharmaceuticals (NASDAQ: SNDX), which is developing entinostat in multiple cancer indications, priced its IPO at $12 per share and raised $52.8 million. The offering price values the company at $208.5 million. The company's VC backers include Domain Associates (19.6% pre-IPO stake), MPM Capital (16.7%) and FMR (11.2%).